GCM
ICPT

Graham Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Graham Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-15,376
Closed -$170K – 1363
2023
Q2 		$170K Buy
+15,376
New +$214K ﹤0.01% 842
2022
Q4 		– Sell
-120,367
Closed -$1.68M – 1433
2022
Q3 		$1.68M Buy
+120,367
New +$1.94M 0.07% 289

Other funds holding ICPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Graham Capital Management's ICPT Position: Q3 2023 in Review

Graham Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2023, closing a stake of 15,376 shares — an estimated $170K sold.

Graham Capital Management first reported a position in ICPT in Q3 2022 and held it in 2 quarters. The position peaked at $1.68M in Q3 2022. 146 funds tracked by Wall St. Rank hold ICPT as of Q3 2023.

  • Graham Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Graham Capital Management sold 15,376 Intercept Pharmaceuticals, Inc. shares in Q3 2023, an estimated $170K.
  • Graham Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2022 and held it in 2 quarters.
  • Graham Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $1.68M in Q3 2022.
  • 146 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2023.

Based on Graham Capital Management's 13F filing for Q3 2023, filed 22 Nov 2023.